Sun Pharma to Acquire Organon for $11.75 Billion at 24% Premium
Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co in an all-cash deal valued at $11.75 billion including Organon’s $8.6 billion net debt, paying $14.00 per share for a 24% premium. The transaction will be funded via cash reserves and committed bank financing, boosting Sun Pharma’s global specialty portfolio.
1. Deal Overview
Sun Pharmaceutical Industries will purchase Organon & Co for $14.00 per share in a $11.75 billion all-cash deal that assumes $8.6 billion of net debt. The transaction represents a 24% premium to Organon’s closing share price on April 24, 2026.
2. Strategic Rationale
The deal expands Sun Pharma’s footprint in high-margin specialty segments such as dermatology, oncology, obesity and women’s health, while providing entry into biosimilars. Organon’s portfolio of over 70 products across 140 countries adds global scale to Sun’s specialty pipeline.
3. Financials and Debt
Sun Pharma plans to finance the acquisition with existing cash reserves and committed bank financing, increasing its consolidated debt from $198.4 million as of December 31, 2025. Strong cash flow is expected to reduce leverage by the third year post-close.
4. Market Reaction
Sun Pharma shares jumped 8.5% on the announcement, marking their largest single-day gain since August 2021 and reflecting investor optimism about the strategic acquisition.